Trial
NCT04262388
A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
University Health Network, Toronto
Collaborators
AstraZeneca
Condition
Pancreatic Ductal Adenocarcinoma
Intervention
Durvalumab
Why stopped
Overall clinical activity (ORR) for oleclumab + durvalumab is minimal across tumor types and does not support further evaluation of this doublet.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-11-17